Comparison between ambulatory infusion mode and inpatient infusion mode from the perspective of quality of life among colorectal cancer patients receiving chemotherapy

International Journal of Nursing Practice

Volumn 16, Issue 5, 2010, Pages 508-516

  Lee, Yik M ^a   Hung, Yuk K ^a   Mo, Frankie KF ^b   Ho, Wing M ^a  

^a HOSPITAL AUTHORITY   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Ambulatory infusion; Chemotherapy; Colorectal cancer; Oncology; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; COLORECTAL TUMOR; COMPARATIVE STUDY; HUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; QUALITY OF LIFE;

EID: 77956801186     PISSN: 13227114     EISSN: 1440172X     Source Type: Journal    
DOI: 10.1111/j.1440-172X.2010.01876.x     Document Type: Article

References (31)

1. Saltz LB, Cox JV, Blanke C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2000, 343:905-914.
2. Douillard JY, Cunningham D, Roth AD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. The Lancet 2000, 355:1041-1047.
3. de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000, 18:2937-2947.
4. Giacchetti S, Perpoint B, Zidani R. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluoroucacil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2000, 18:136-147.
5. Tucker EM. Drug administration systems for infusion chemotherapy. Cancer Chemotherapy by Infusion 1987, 41-58. Lokich JJ. In, ed, Chicago, IL, USA, Precept Press
6. Morales JO, Von Behren L. Secondary bacterial infections in HIV-infected patients: An alternative ambulatory outpatient treatment utilizing intravenous cefotaxime. American Journal of Medicine 1994, 97(2A):9-13. Suppl
7. Graham DR. Nosohusial infection: Complication of home intravenous therapy. Infectious Disease of Clinical Practice 1993, 2:158-161.
8. Williams DN. Home intravenous anti-infective therapy (HIVAT): Do the benefits outweigh the risks. Drug Safety 1996, 14:1-7.
9. Birnbaum HG, Tang M. The home infusion therapy/relative benefit index: Summary of an analysis using insurance claims data. Medical Care 1998, 36:757-765.
10. Wright RA. Antibiotic therapy: How to make outpatient IV therapy effective and cost effective. Consultant 1996, 36:280-297.
11. Rowe M, Valle JW, Swindell R, Fitzsimmons L, James RD. New face for a familiar friend: The deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: A feasibility study. Journal of Oncology Pharmaceutical Practice 2002, 8:97-103.
12. Sakuyama T. Home chemotherapy by concomitant UFT and leukovorin in post-operative colorectal cancer patients assessed with Dukes D and curative C colorectal cancer. Japanese Journal of Cancer and Chemotherapy 2004, 31:771-775.
13. Midorikawa Y, Nakachi T, Kasuga T. Our outpatient cases or home anti-cancer chemotherapy using CV port and a portable pump system. Japanese Journal of Cancer and Chemotherapy 2006, 33(2):264-266. Suppl
14. King MT, Hall J, Caleo S, Gurney HP, Harnett PR. Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy. International Journal of Health Services 2000, 30:557-579.
15. Borras JM, Sanchez-Hernandez A, Navarro M. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: A randomized controlled trial. British Medical Journal 2001, 322:826-828.
16. Rapsilber L, Camp-Sorrell D. Ambulatory infusion pumps: Application to oncology. Seminars in Oncology Nursing 1995, 11:213-220.
17. Goski LA, Grothman L. Home infusion therapy. Seminars in Oncology Nursing 1996, 12:193-201.
18. Fayers PM, Aeeronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual 2001, on behalf of the EORTC Quality of Group, 3rd, edn., Brussels, European Organization for Research and Treatment of Cancer
19. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: An analysis of published studies. Annals of Oncology 2004, 15:712-720.
20. Berger AM, Farr L. The influence of daytime and night-time restlessness on cancer-related fatigue. Oncology Nursing Forum 1999, 26:1663-1671.
21. Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum 2000, 27:1443-1448.
22. Morrow GR, Roscoe JA, Hickok JT, Andrews PR, Matteson S. Nausea and emesis: Evidence for a biobehavioral perspective. Supportive Care in Cancer 2002, 10:96-105.
23. Morrow GR, Roscoe JA, Hickok JT. Nausea and vomiting. Psycho-Oncology 1998, 476-484. Holland JC, In, ed, 2nd, edn., New York, Oxford University Press
24. Chan A, Hui E. Handbook for Non-investigative Systemic Therapy Protocols 2008, 3rd, edn., Hong Kong, Department of Clinical Oncology, Prince of Wales Hospital
25. Yeo W, Mo FK, Suen JJ. A randomized study of aprepitant, ondansetron and dexamethason for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic. Breast Cancer Research and Treatment 2009, 113:529-535.
26. Warr DG, Hesketh PJ, Gralla RJ. Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Journal of Clinical Oncology 2005, 23:2822-2830.
27. Osoba D, Zee B, Warr D, Latreille L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Supportive Care in Cancer 1997, 5:307-313.
28. Bender CM, McDaniel RW, Murphy-Ende K. Chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing 2002, 6:94-102.
29. Reville B, Almadrones L. Continuous infusion chemotherapy in the ambulatory setting: The nurse's role in patient selection and education. Oncology Nursing Forum 1989, 16:529-535.
30. Tice AD. Outpatient parenteral antibiotic therapy. Management of serious infection, Part I; medical, socioeconomic, and legal issues. The team concept. Hospital Practice 1993, 28(1):6-10. Suppl
31. Johansson E, Langius-Eklof A, Engervall P, Wredling R. Patients' experience of ambulatory self-administration of pamidronate in multiple myeloma. Cancer Nursing 2005, 28:158-165.